NEW DATA SUGGESTS IMPROVED TUMOR RESPONSE FOR THE COMBINATION OF AZIXA® AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
June 28, 2016 02:30 ET | Immune Pharmaceuticals Inc
NEW DATA SUGGESTS IMPROVED TUMOR RESPONSE FOR THE COMBINATION OF AZIXA AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER Immune Pharmaceuticals Files New Provisional Patent...
Immune Pharmaceuticals' Common Stock Approved for Trading on NASDAQ OMX First North Premier
November 26, 2013 00:38 ET | Immune Pharmaceuticals Inc
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 26, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that its common stock has...
Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
November 20, 2013 03:14 ET | Immune Pharmaceuticals Inc
  GAIN ON MERGER TRANSACTION DRIVES INCREASE IN STOCKHOLDERS' EQUITY TO $7.8 MILLION TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 20, 2013 /PRNewswire/ -- Immune Pharmaceuticals...
Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
November 01, 2013 02:08 ET | Immune Pharmaceuticals Inc
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 1, 2013  -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that it has appointed Erik Penser...
New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis
October 16, 2013 00:43 ET | Immune Pharmaceuticals Inc
Phase II Trial to Focus on Moderate to Severe UC Patients with Eotaxin-1 Biomarker   TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 16, 2013 /PRNewswire/ -- Immune Pharmaceuticals...
Immune Pharmaceuticals Announces Changes to its Board of Directors
October 15, 2013 01:04 ET | Immune Pharmaceuticals Inc
New Members Provide strong financing and operating experience   TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 15, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX...
IMMUNE Pharmaceuticals Inc. to Present at 12th Annual BIO Investor Forum
October 03, 2013 00:37 ET | Immune Pharmaceuticals Inc
TARRYTOWN, N.Y., Oct. 3, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Dr. Daniel G. Teper, Company Chairman and CEO,...
Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
September 30, 2013 03:16 ET | Immune Pharmaceuticals Inc
Company to Transfer Swedish Listing to NASDAQ OMX First North Premier TARRYTOWN, N.Y., Sept. 30, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange and OTCQX: IMNP)...
Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform
September 23, 2013 00:57 ET | Immune Pharmaceuticals Inc
TARRYTOWN, N.Y., Sept. 23, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced today that effective September 23, 2013...
Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013
September 04, 2013 03:07 ET | Immune Pharmaceuticals Inc
TARRYTOWN, N.Y., Sept. 4, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) today announced it will be featured as a presenting company at the...